Jim Cramer's Mad Dash: Good News for Regeneron

NEW YORK (TheStreet) -- Shares of Regeneron (REGN) are up almost 10% in Wednesday's trading session, and the stock was the focus on CNBC's "Cramer's Mad Dash" segment.   

The company is having a "breakthrough" with its cholesterol drug. Its other drug, Eylea, was just approved by the Food and Drug Administration following positive Phase III results, according to TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio

It's cholesterol treatment is the world's first alternative to statin drugs, which many people are allergic too, he said. 

Biotechnology stocks continue to move higher, while large-cap pharmaceutical stocks remain stagnant amid slower growth. 

Gilead Sciences (GILD) is the "cheapest drug company I follow," Cramer concluded, before adding that Regeneron's cholesterol drug could become a household product in the future.

-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

Why a Global Stock Market Crash Is Coming

Why a Global Stock Market Crash Is Coming

3 New Investing Myths That Must Be Busted

3 New Investing Myths That Must Be Busted

Sears CEO Eddie Lampert Looks Like He Is Sucking Company Dry

Sears CEO Eddie Lampert Looks Like He Is Sucking Company Dry

Nasdaq Exec: Exchange Is 'All-In' on Using Blockchain Technology

Nasdaq Exec: Exchange Is 'All-In' on Using Blockchain Technology

It's Dumb to Think Legalizing Weed Is Still a Political Issue

It's Dumb to Think Legalizing Weed Is Still a Political Issue